Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Ravindra UppaluriKatie M CampbellAnn Marie EgloffPaul ZolkindZachary L SkidmoreBrian NussenbaumRandal C PanielloJason T RichRyan JacksonPatrik PipkornLoren S MichelJessica LeyPeter OppeltGavin P DunnErica K BarnellNicholas C SpiesTianxiang LinTiantian LiDavid T MulderYoustina HannaIulia CirlanTrevor J PughTenny MudiantoRachel RileyLiye ZhouVickie Y JoMatthew D StachlerGlenn J HannaJason KassRobert HaddadJonathan D SchoenfeldEvisa GjiniAna LakoWade ThorstadHiram A GayMackenzie DalyScott J RodigIan S HagemannDorina KallogjeriJay F PiccirilloRebecca D ChernockMalachi GriffithMalachi GriffithDouglas R AdkinsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The 1-year relapse rate in patients with high-risk pathology was lower than historical.